drugset / Trial / NCT05329051
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with Comirnaty.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2022-09-01
- Completion
- 2023-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BNT162b2 | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | SCTV01E | Vaccine | — | Intramuscular |